{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:40:40Z","timestamp":1787614840617,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02153-z","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:45:04Z","timestamp":1778737504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pre-transplant JAK-inhibition improves post-transplant outcome in myelofibrosis"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-5264","authenticated-orcid":false,"given":"Patrycja","family":"Zieli\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Wieczorkiewicz-Kabut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Spa\u0142ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kopi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kocl\u0119ga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Wo\u017aniczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Boral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Butrym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"2153_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Primary myelofibrosis. 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:801\u201321. https:\/\/doi.org\/10.1002\/ajh.26857.","journal-title":"Am J Hematol"},{"key":"2153_CR2","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","volume":"11","author":"N Kr\u00f6ger","year":"2024","unstructured":"Kr\u00f6ger N, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group. Lancet Haematol. 2024;11:e62\u201374. https:\/\/doi.org\/10.1016\/S2352-3026(23)00305-8.","journal-title":"Lancet Haematol"},{"key":"2153_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703\u20138. https:\/\/doi.org\/10.1182\/blood-2009-09-245837.","journal-title":"Blood"},{"key":"2153_CR4","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392\u20137. https:\/\/doi.org\/10.1200\/JCO.2010.32.2446.","journal-title":"J Clin Oncol"},{"key":"2153_CR5","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70\u2009+\u2009Version 2.0: Mutation and karyotype-enhanced International Prognostic Scoring System for primary myelofibrosis. J Clin Oncol. 2018;36:1769\u201370. https:\/\/doi.org\/10.1200\/JCO.2018.78.9867.","journal-title":"J Clin Oncol"},{"key":"2153_CR6","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32:1631\u201342. https:\/\/doi.org\/10.1038\/s41375-018-0107-z.","journal-title":"Leukemia"},{"key":"2153_CR7","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/leu.2017.169","volume":"31","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31:2726\u201331. https:\/\/doi.org\/10.1038\/leu.2017.169.","journal-title":"Leukemia"},{"key":"2153_CR8","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/ajh.27670","volume":"100","author":"S Fathima","year":"2025","unstructured":"Fathima S, Abdelmagid M, Alsugair A, et al. Multihit TP53 Mutations in myeloproliferative neoplasms and acute myeloid leukemia: comparative analysis of survival and risk factors in 142 informative cases. Am J Hematol. 2025;100:1010\u201318. https:\/\/doi.org\/10.1002\/ajh.27670.","journal-title":"Am J Hematol"},{"key":"2153_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557.","journal-title":"N Engl J Med"},{"key":"2153_CR10","doi-asserted-by":"publisher","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ et al. COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013; 122:4047-53. Erratum in: Blood. 2016 128:3013. https:\/\/doi.org\/10.1182\/blood-2016-11-750505. PMID: 24174625.","DOI":"10.1182\/blood-2016-11-750505"},{"key":"2153_CR11","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41409-025-02701-3","volume":"60","author":"R Greco","year":"2025","unstructured":"Greco R, Ruggeri A, McLornan DP, et al. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transpl. 2025;60:1499\u2013525. https:\/\/doi.org\/10.1038\/s41409-025-02701-3.","journal-title":"Bone Marrow Transpl"},{"key":"2153_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41408-025-01235-7","volume":"15","author":"J Thiele","year":"2025","unstructured":"Thiele J, Kvasnicka HM, Gianelli U, et al. Evolution of WHO diagnostic criteria in Classical Myeloproliferative Neoplasms compared with the International Consensus Classification. Blood Cancer J. 2025;15:31. https:\/\/doi.org\/10.1038\/s41408-025-01235-7.","journal-title":"Blood Cancer J"},{"key":"2153_CR13","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-2004.","journal-title":"Blood"},{"key":"2153_CR14","doi-asserted-by":"publisher","unstructured":"Sureda A, Carpenter PA, Bacigalupo A et al. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transplant. 2024; 59:832-7. https:\/\/doi.org\/10.1038\/s41409-024-02251-0. Erratum in: Bone Marrow Transplant. 2024; 59:1335. doi: 10.1038\/s41409-024-02336-w.","DOI":"10.1038\/s41409-024-02251-0"},{"key":"2153_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl. 2016;22:4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2153_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389\u2013e4011. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2153_CR17","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128\u201332.","journal-title":"Haematologica"},{"key":"2153_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02732-w","author":"P Sobieralski","year":"2025","unstructured":"Sobieralski P, Czerw T, Gras L, et al. Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transpl. 2025. https:\/\/doi.org\/10.1038\/s41409-025-02732-w. Epub ahead of print.","journal-title":"Bone Marrow Transpl"},{"key":"2153_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/10428194.2024.2422835","volume":"66","author":"N Sharma","year":"2025","unstructured":"Sharma N, Loscocco GG, Gangat N, et al. When and how to transplant in myelofibrosis - recent trends. Leuk Lymphoma. 2025;66:359\u201377. https:\/\/doi.org\/10.1080\/10428194.2024.2422835.","journal-title":"Leuk Lymphoma"},{"key":"2153_CR20","doi-asserted-by":"publisher","unstructured":"McLornan DP, Hernandez-Boluda JC, Czerw T et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. Leukemia. 2021; 35:2445-59. https:\/\/doi.org\/10.1038\/s41375-021-01294-2. Erratum in: Leukemia. 2021; 35:3625. doi: 10.1038\/s41375-021-01395-y.","DOI":"10.1038\/s41375-021-01294-2"},{"key":"2153_CR21","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bbmt.2017.09.016","volume":"24","author":"BT Samuelson Bannow","year":"2018","unstructured":"Samuelson Bannow BT, Salit RB, Storer BE, et al. Hematopoietic cell transplantation for myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk predicts post-transplant outcomes. Biol Blood Marrow Transpl. 2018;24:386\u201392. https:\/\/doi.org\/10.1016\/j.bbmt.2017.09.016.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2153_CR22","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3324\/haematol.2011.061168","volume":"97","author":"M Ditschkowski","year":"2012","unstructured":"Ditschkowski M, Elmaagacli AH, Trenschel R, et al. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica. 2012;97:1574\u201381. https:\/\/doi.org\/10.3324\/haematol.2011.061168.","journal-title":"Haematologica"},{"key":"2153_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","volume":"3","author":"H Ali","year":"2019","unstructured":"Ali H, Aldoss I, Yang D, et al. MIPSS70\u2009+\u2009v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen. Blood Adv. 2019;3:83\u201395. https:\/\/doi.org\/10.1182\/bloodadvances.2018026658.","journal-title":"Blood Adv"},{"key":"2153_CR24","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.bbmt.2020.07.022","volume":"26","author":"JC Hern\u00e1ndez-Boluda","year":"2020","unstructured":"Hern\u00e1ndez-Boluda JC, Pereira A, Alvarez-Larran A, et al. Predicting survival after allogeneic hematopoietic cell transplantation in myelofibrosis: performance of the Myelofibrosis Transplant Scoring System (MTSS) and development of a new prognostic model. Biol Blood Marrow Transpl. 2020;26:2237\u201344. https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.022.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2153_CR25","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","volume":"133","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Ditschkowski M, Bogdanov R, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133:2233\u201342. https:\/\/doi.org\/10.1182\/blood-2018-12-890889.","journal-title":"Blood"},{"key":"2153_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/bmt.2013.173","volume":"49","author":"N Jaekel","year":"2014","unstructured":"Jaekel N, Behre G, Behning A, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transpl. 2014;49:179\u201384. https:\/\/doi.org\/10.1038\/bmt.2013.173.","journal-title":"Bone Marrow Transpl"},{"key":"2153_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/ejh.13099","volume":"101","author":"S Shahnaz Syed Abd Kadir","year":"2018","unstructured":"Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, et al. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Eur J Haematol. 2018;101:305\u201317. https:\/\/doi.org\/10.1111\/ejh.13099.","journal-title":"Eur J Haematol"},{"key":"2153_CR28","doi-asserted-by":"publisher","first-page":"63672501446","DOI":"10.1016\/j.jtct.2025.09.020","volume":"S2666\u2013","author":"RB Salit","year":"2025","unstructured":"Salit RB, Fan X, Gooley TA, et al Pre-hematopoietic cell transplantation ruxolitinib in transplantation-eligible patients with myelofibrosis: long-term outcomes of a phase II prospective study. Transpl Cell Ther. 2025;S2666\u2013:63672501446\u20130. . https:\/\/doi.org\/10.1016\/j.jtct.2025.09.020.","journal-title":"Transpl Cell Ther"},{"key":"2153_CR29","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/s41409-021-01252-7","volume":"56","author":"M Robin","year":"2021","unstructured":"Robin M, Porcher R, Orvain C, et al. Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups. Bone Marrow Transpl. 2021;56:1888\u201399. https:\/\/doi.org\/10.1038\/s41409-021-01252-7.","journal-title":"Bone Marrow Transpl"},{"key":"2153_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.bbmt.2020.01.010","volume":"26","author":"S Chhabra","year":"2020","unstructured":"Chhabra S, Narra RK, Wu R, et al. Fludarabine\/busulfan conditioning-based allogeneic hematopoietic cell transplantation for myelofibrosis: role of ruxolitinib in improving survival outcomes. Biol Blood Marrow Transpl. 2020;26:893\u2013901. https:\/\/doi.org\/10.1016\/j.bbmt.2020.01.010.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2153_CR31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.bbmt.2018.09.001","volume":"25","author":"V Gupta","year":"2019","unstructured":"Gupta V, Kosiorek HE, Mead A, et al. Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transpl. 2019;25:256\u201364. https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.001.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2153_CR32","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1182\/bloodadvances.2021005035","volume":"6","author":"H Ali","year":"2022","unstructured":"Ali H, Tsai NC, Synold T, et al. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Adv. 2022;6:1444\u201353. https:\/\/doi.org\/10.1182\/bloodadvances.2021005035.","journal-title":"Blood Adv"},{"key":"2153_CR33","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","volume":"24","author":"N Kr\u00f6ger","year":"2018","unstructured":"Kr\u00f6ger N, Shahnaz Syed Abd Kadir S, Zabelina T, et al. Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation. Biol Blood Marrow Transpl. 2018;24:2152\u20136. https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.023.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2153_CR34","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.3390\/cancers16193257","volume":"16","author":"S Machherndl-Spandl","year":"2024","unstructured":"Machherndl-Spandl S, Hannouf S, Nikoloudis A, et al. Improved outcomes in myelofibrosis after allogeneic stem-cell transplantation in the era of ruxolitinib pretreatment and intensified conditioning regimen-single-center analysis. Cancers (Basel). 2024;16:3257. https:\/\/doi.org\/10.3390\/cancers16193257.","journal-title":"Cancers (Basel)"},{"key":"2153_CR35","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/leu.2014.86","volume":"28","author":"T St\u00fcbig","year":"2014","unstructured":"St\u00fcbig T, Alchalby H, Ditschkowski M, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET\/PV myelofibrosis. Leukemia. 2014;28:1736\u20138. https:\/\/doi.org\/10.1038\/leu.2014.86.","journal-title":"Leukemia"},{"key":"2153_CR36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","volume":"22","author":"M Shanavas","year":"2016","unstructured":"Shanavas M, Popat U, Michaelis LC, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus Kinase 1\/2 inhibitors. Biol Blood Marrow Transpl. 2016;22:432\u201340. https:\/\/doi.org\/10.1016\/j.bbmt.2015.10.005.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2153_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/ajh.27529","volume":"100","author":"K Rathje","year":"2025","unstructured":"Rathje K, Gagelmann N, Badbaran A, et al. Clinical and immune effects of peri-transplantation JAK inhibition for myelofibrosis. Am J Hematol. 2025;100:200\u20139. https:\/\/doi.org\/10.1002\/ajh.27529.","journal-title":"Am J Hematol"},{"key":"2153_CR38","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1111\/bjh.15967","volume":"186","author":"JJ Pu","year":"2019","unstructured":"Pu JJ, Poulose J, Malysz J, et al. Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant-a pilot study. Br J Haematol. 2019;186:e130\u20133. https:\/\/doi.org\/10.1111\/bjh.15967.","journal-title":"Br J Haematol"},{"key":"2153_CR39","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00277-025-06270-9","volume":"104","author":"SA Wall","year":"2025","unstructured":"Wall SA, Tamari R, DeFilipp Z, Hobbs GS. Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes. Ann Hematol. 2025;104:2125\u201341. https:\/\/doi.org\/10.1007\/s00277-025-06270-9.","journal-title":"Ann Hematol"},{"key":"2153_CR40","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","volume":"6","author":"M Maffioli","year":"2022","unstructured":"Maffioli M, Mora B, Ball S, et al. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv. 2022;6:1855\u201364. https:\/\/doi.org\/10.1182\/bloodadvances.2021006889.","journal-title":"Blood Adv"},{"key":"2153_CR41","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","volume":"35","author":"N Kr\u00f6ger","year":"2021","unstructured":"Kr\u00f6ger N, Sbianchi G, Sirait T, et al. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia. 2021;35:3551\u201360. https:\/\/doi.org\/10.1038\/s41375-021-01276-4.","journal-title":"Leukemia"},{"key":"2153_CR42","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/S2352-3026(22)00330-1","volume":"10","author":"N Polverelli","year":"2023","unstructured":"Polverelli N, Hern\u00e1ndez-Boluda JC, Czerw T, et al. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023;10:e59\u201370. https:\/\/doi.org\/10.1016\/S2352-3026(22)00330-1.","journal-title":"Lancet Haematol"},{"key":"2153_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ajh.26020","volume":"96","author":"N Polverelli","year":"2021","unstructured":"Polverelli N, Mauff K, Kr\u00f6ger N, et al. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). Am J Hematol. 2021;96:69\u201379. https:\/\/doi.org\/10.1002\/ajh.26020.","journal-title":"Am J Hematol"},{"key":"2153_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ajh.26034","volume":"96","author":"JB Bossard","year":"2021","unstructured":"Bossard JB, Beuscart JB, Robin M, et al. Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC), the France-Intergroupe des Syndromes My\u00e9loprolif\u00e9ratifs (FIM) and the Agence de la BioM\u00e9decine (ABM). Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study. Am J Hematol. 2021;96:80\u20138. https:\/\/doi.org\/10.1002\/ajh.26034.","journal-title":"Am J Hematol"},{"key":"2153_CR45","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/ajh.27252","volume":"99","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Hobbs GS, Campodonico E, et al. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis. Am J Hematol. 2024;99:844\u201353. https:\/\/doi.org\/10.1002\/ajh.27252.","journal-title":"Am J Hematol"},{"key":"2153_CR46","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.bbmt.2006.05.015","volume":"12","author":"AS Artz","year":"2006","unstructured":"Artz AS, Pollyea DA, Kocherginsky M, et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2006;12:954\u201364. https:\/\/doi.org\/10.1016\/j.bbmt.2006.05.015.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2153_CR47","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/ajh.27262","volume":"99","author":"N Polverelli","year":"2024","unstructured":"Polverelli N, Bonneville EF, de Wreede LC, et al. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT. Am J Hematol. 2024;99:993\u20136. https:\/\/doi.org\/10.1002\/ajh.27262.","journal-title":"Am J Hematol"},{"key":"2153_CR48","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1182\/bloodadvances.2024013451","volume":"8","author":"T Jain","year":"2024","unstructured":"Jain T, Estrada-Merly N, Salas MQ, et al. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study. Blood Adv. 2024;8:4281\u201393. https:\/\/doi.org\/10.1182\/bloodadvances.2024013451.","journal-title":"Blood Adv"},{"key":"2153_CR49","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/ajh.70049","volume":"100","author":"JC Hern\u00e1ndez-Boluda","year":"2025","unstructured":"Hern\u00e1ndez-Boluda JC, Sheth V, Iacobelli S, et al. Impact of donor type on outcomes after allogeneic hematopoietic cell transplantation in myelofibrosis: a study on behalf of the Chronic Malignancies Working Party of the EBMT. Am J Hematol. 2025;100:2028\u201339. https:\/\/doi.org\/10.1002\/ajh.70049.","journal-title":"Am J Hematol"},{"key":"2153_CR50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3324\/haematol.2010.031831","volume":"96","author":"C Elena","year":"2011","unstructured":"Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica. 2011;96:167\u201370. https:\/\/doi.org\/10.3324\/haematol.2010.031831.","journal-title":"Haematologica"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02153-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02153-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02153-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:07:48Z","timestamp":1783465668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02153-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2153"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02153-z","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The consent of Ethics Committee was not required in view of the retrospective nature of the study. All the procedures being performed were part of the routine care. JAK inhibitors are approved treatment for myelofibrosis patients. Allogeneic stem cell transplantation remains a standard of care for hematological patients as per EBMT recommendations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Complete anonymity of patients was assured enabling disclosure of their identity.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent to publish"}}],"article-number":"252"}}